四维模拟图像引导加速部分乳腺照射可行性研究中的患者报告结局与美容效果
本研究纳入年龄≥50岁、Karnofsky体能状态评分≥70、0期和I期乳腺癌保乳术后切缘≥2 mm、病理肿瘤大小≤2 cm的女性,采用四维计算机断层扫描模拟、0.2 cm而非标准1.0 cm的计划靶体积及每日图像引导,处方剂量3850 cGy分10次。主要终点可行性达标:乳腺V50中位数31%、V100中位数11%;3年内无复发、无>3级毒性;至第3年不良美容效果较基线增加13.2%(至15.4%),患者决策满意度完全达到84.2%。
要点
- 四维模拟图像引导APBI可行性达标:乳腺V50中位数31%、V100中位数11%。
- 3年内无局部区域复发,无>3级毒性。
- 不良美容效果从基线2.2%增至第3年15.4%,增加13.2%;决策满意度完全达到84.2%。
核心结论
- 采用四维模拟、严格剂量学约束和图像引导放疗的APBI可获得可接受的美容效果,3年内无局部区域复发且无>3级毒性,美容效果下降幅度与既往发表研究相比可接受,患者对APBI满意度极好。
研究设计与样本
- 可行性研究,纳入年龄≥50岁、Karnofsky体能状态评分≥70、0期和I期乳腺癌保乳术后切缘≥2 mm、病理肿瘤大小≤2 cm的女性,采用四维计算机断层扫描模拟、计划靶体积0.2 cm而非标准1.0 cm,处方剂量3850 cGy分10次;若≥50%入组者满足乳腺剂量学约束(V50<45%和V100<23.5%)则认为研究成功。
主要发现
- 研究达到降低非靶乳腺剂量可行性的主要终点,乳腺V50中位数31%、V100中位数11%。
- 无复发,无>3级毒性。
- 基线时美容效果一般/差的比例低(2.2%),至第3年APBI后不良美容效果增加13.2%(至15.4%)。
- 患者决策满意度完全达到84.2%。
关键数值与推荐
- 可行性成功标准为≥50%入组者满足乳腺V50<45%和V100<23.5%。
- 处方剂量3850 cGy分10次,计划靶体积0.2 cm而非标准1.0 cm。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Three-dimensional conformal accelerated partial breast irradiation (APBI) is a treatment option for well selected women with breast cancer, despite reports of adverse cosmetic outcome with this technique. Dose-volume relationships may be responsible for this poor cosmesis. We aimed to determine the feasibility of limiting the exposure of nontarget breast tissue to radiation through smaller planning target volumes achieved through daily image guidance and 4-dimensional computed tomography simulation. METHODS AND MATERIALS: Eligibility criteria included the following: women, age ≥50 years, Karnofsky performance status score ≥70, stage 0 and I breast cancer treated with breast-conserving surgery, margins clear by ≥2 mm, pathologic tumor size ≤2 cm, and 4-dimensional computed tomography with planning target volumes of 0.2 cm rather than the standard 1.0 cm. A dose of 3850 cGy was prescribed in 10 fractions. The study was considered successful if ≥50% of enrollees met dosimetric constraints on the breast (V50 < 45% and V100 < 23.5%). RESULTS: The study achieved its primary endpoint of feasibility of reducing the nontarget breast dose with a breast median of V50 = 31% and V100 = 11%. There were no recurrences and no toxicity grade >3. At baseline, fair/poor cosmesis was low (2.2%). By year 3, adverse cosmesis post-APBI had increased by 13.2% (to 15.4%). Patient decisional satisfaction was reached completely in 84.2% of patients. CONCLUSIONS: This study demonstrated that with 4-dimensional simulated APBI that uses stringent dosimetric constraints and image guidance radiation therapy, it is possible to obtain acceptable cosmetic outcomes. We report no locoregional recurrences in 3 years and no toxicity grade >3. The observed decline in cosmesis was acceptable compared with that of prior published studies, and patient satisfaction with APBI was excellent.
引用
- Rahimy E, Weidhaas J, Wei W, et al. Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Pract Radiat Oncol. 2019. PMID: 30796975. doi:10.1016/j.prro.2019.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。